Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst

2026-03-05 12:01:40 ET

Investment Overview

New York headquartered Sellas Life Sciences ( SLS ) listed on the Nasdaq in August 2017 via a merger with struggling biotech Galena Biopharma - a press release at the time stated:

SELLAS’ lead asset, galinpepimut-S (GPS), is a Wilm’s Tumor 1 (WT1)-targeting peptide-based immunotherapeutic being developed as a monotherapy and in combination with checkpoint inhibitors in multiple tumor settings.

The WT1 antigen is one of the most widely expressed cancer antigens in multiple malignances. Galinpepimut-S is a multi-peptide product with heteroclitic-modifications that enhance the immunity and duration of the immune response against the WT1 antigen independent of a patient’s underlying genetics (HLA types) and elicits CD4 and CD8 immune responses with clinical efficacy and favorable safety profile.

GPS is initially being developed for the treatment of acute myeloid leukemia (AML) and is Phase 3-ready in this setting.

Read the full article on Seeking Alpha

For further details see: